Introduction

Key Points

• Adjuvant hormone therapy is given after surgery to lower the risk of the cancer returning.
  
  
• Hormone therapy for women who have gone through menopause and have hormone receptor-positive breast cancer includes tamoxifen and/or an aromatase inhibitor.
  
  
• These drugs have different side effects and women should speak with their doctors about their options for hormone therapy, including the risks and benefits of the available drugs and how long to take each drug.

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) asks its medical experts to develop recommendations for specific areas of cancer care. In 2002, ASCO developed a clinical practice guideline about the use of aromatase inhibitors for early-stage breast cancer. This guideline was updated in 2003 and again in 2004 to reflect the results of clinical trials for aromatase inhibitors. This guide for patients is based on ASCO's recommendations.

As you read this guide, please keep in mind that every person treated for cancer is different. These recommendations are not meant to replace your judgment or that of your doctor. The final decisions you and your doctors make will be based on your individual circumstances.

Last Updated: November 15, 2004

| Next >